Hi readers,
There was a lot of fanfare this month over canine longevity startup Loyal’s milestone Series C round, which raised US$100 million. This of course got us thinking about cats, and the current state of feline longevity therapeutics.
The feline longevity space is currently led by The Cat Health Company (whom we interviewed last November). Despite only launching in 2024, the company has raised around US$1.7 million in funding and is developing treatments for age-related diseases such as sarcopenia, cognitive decline and arthritis.
Meanwhile, Loyal is targeting metabolic ageing through its lead candidate LOY-002, with the aim of delaying age-associated disease.
That said, the market opportunity for cats (a significantly underserved species) is very different than for dogs.
Unlike for dogs, feline medicine still lacks adequate options for many chronic conditions. This means that the introduction of effective chronic disease therapeutics is likely to have a disproportionate impact on feline lifespan.
A major case in point: feline obesity.
With obesity affeting nearly two-thirds of cats in the USA, the arrival of targeted obesity therapeutics such as GLP-1s may represent the most immediate (and scalable) driver of feline longevity.
This week, we examine the anticipated launch of GLP-1–based therapies for feline obesity, and what they could mean for the emerging feline longevity market.
What we’re watching
Will obesity therapeutics define the feline longevity market?
The more we love our cats, the more we tend to feed them.
However, this I-love-you-so-I-feed-you habit has contributed to rising obesity rates in cats, with as much as 61% of domestic cats overweight or obese in the USA, according to the Association for Pet Obesity Prevention. Lifestyle factors such as indoor confinement, high-calorie diets, and feeding behaviours are the main drivers.
Obesity has a stark effect on longevity. In cats, a 2.8-fold increase in mortality has been demonstrated in obese cats versus lean cats. Not only that, obesity also predispose felines to diseases such as diabetes and cancer.
But here’s the key: unlike many chronic conditions, cat guardians often have direct behavioural influence over their cat’s diet.
As the feline longevity economy emerges, targeting obesity could be one of the earliest and most scalable opportunities to lengthen feline lifespan.
The emerging feline longevity economy
Compared with dogs, the feline longevity sector is still in its infancy.
Earlier this month, canine longevity biotech Loyal announced that it had raised US$100 million in Series C funding. This brings the total raised to over US$250 million since it was founded in 2019.
Meanwhile, the leader in the feline longevity space, The Cat Health Company, has raised approximately US$1.74 million since it was founded in 2024.
Loyal’s lead candidate, LOY-002, targets canine metabolic processes in order to delay age-related disease, while The Cat Health Company focuses on age-related conditions such as sarcopenia and mobility (read our interview with The Cat Health Company here).
Given the relative lack of therapeutic options for chronic diseases in cats, however, it’s likely that the biggest longevity gains in the near future will come from treating highly prevalent diseases such as obesity.
All eyes on GLP-1s
Huadong Medicine is the frontrunner in the race to bring to market a GLP-1 class feline obesity treatment.
Obesity management in cats has traditionally focused on diet control and caloric restriction.
However, studies indicate that only roughly half of cats in dietary weight-loss programmes tend to achieve target weight, and that the most obese cats are less likely to succeed without adjunctive interventions.
Enter next-generation pharmacotherapies: GLP-1 (glucagon-like peptide-1) receptor agonists. This treatment class are well-known for their transformative effect in humans, and have now entered clinical research in cats.
Huadong Medicine: In December 2025, China-based Huadong Medicine filed for regulatory approval in China for its GLP-1 agonist candidate, pribopeptide, targeting feline obesity.
Akston: Evaluating once-weekly GLP-1 Fc-fusion AKS-562c in an ~11-week Cornell University study to assess weight loss in overweight client-owned cats.
OKAVA/Vivani: Developing OKV-119 (subcutaneous exenatide delivery system) for overweight or obese client-owned cats.
Vetmab Biosciences: Filed a patent application in October 2024 for a GLP-1 receptor agonist intended for dogs, cats, and horses.
The current wave of GLP-1–based feline obesity treatment candidates therefore represents one of the first areas R&D can be expected to produce measurable changes in feline longevity.
For both investors and innovators, this makes obesity therapeutics one of the most investible areas in an otherwise early-stage space.
Feline obesity candidates: A growing space
Though still early-stage, the concentration of GLP-1-based programs underscores obesity’s emergence as one of the first realistic, fundable opportunities in feline longevity.
Candidate | Developer | Milestone |
pribopeptide (long-acting injectable) | Huadong Medicine | Regulatory approval (~2026) |
AKS-562c (GLP-1 Fc-fusion) | Akston / Cornell Univ. | Topline safety & weight loss data (~2026) |
OKV-119 (exenatide implant) | OKAVA / Vivani Medical | Initial tolerability data, pilot dosing series (~2026) |
Semaglutide analogues | Concept models | N/A |
Peptide YY / dual incretin modulators | Academic / early-stage biotech interest | Exploratory models |
YP05002 | Pfizer / YaoPharma, all indications in animals and humans). | Phase I data, ~April 2026. |
Feline Business Brief provides market intelligence on the global feline economy. We analyse early signals, emerging risks and structural shifts across feline nutrition, health, therapeutics, diagnostics, technology and retail.